# Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka

> **NCT01803425** · — · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Immunisation Against Streptococcus Pneumoniae

## Interventions

- **OTHER:** Synflorix™ data collection

## Key facts

- **NCT ID:** NCT01803425
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it was concluded GSK will submit local PSURs.
- **Last updated:** 2013-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803425, "Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01803425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*